Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies

Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Pinometostat (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Epizyme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 49).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top